Omicron gRBD-ferritin nanoparticle

Omicron gRBD-ferritin nanoparticle is a recombinant protein subunit vaccine candidate designed to provide broad protection against the SARS-CoV-2 Omicron variant and its sublineages. The vaccine utilizes a self-assembling ferritin nanoparticle platform to display 24 copies of a glycosylated Receptor Binding Domain (gRBD) derived from the Omicron variant's Spike protein. This multivalent presentation mimics the repetitive antigenic structure of a virus, which enhances B-cell receptor cross-linking and stimulates a more robust and diverse neutralizing antibody response compared to monomeric RBD vaccines. Developed by researchers at Sun Yat-sen University and Guangzhou Medical University, the "gRBD" modification involves specific glycosylation patterns intended to improve the stability of the protein and focus the immune response on conserved, neutralizing epitopes. Preclinical studies and early-phase clinical trials have indicated that this nanoparticle approach can elicit high titers of antibodies capable of neutralizing multiple SARS-CoV-2 variants of concern.

Other names

Omicron-specific gRBD-ferritin nanoparticle vaccinegRBD-ferritinOmicron-gRBD-ferritin